红细胞免疫化是骨髓增生异常综合征生存的独立预测因素
本研究分析486例输血依赖的骨髓增生异常综合征(MDS)患者,以时间依赖协变量评估红细胞免疫化(同种或自身抗体)的预后影响。红细胞免疫化与剩余生存显著独立降低相关(HR 11.9,95%CI 7.3-19.6,p=0.001),且不预测向急性髓系白血病(AML)进展。
要点
- 红细胞免疫化是输血依赖MDS患者生存的独立不良预后因素。
- MDS诊断前输血和Rh(D)阴性血型与免疫化风险升高相关。
- 免疫化不预测AML进展,但免疫化后输血强度增加。
核心结论
- 红细胞免疫化与输血依赖MDS患者剩余生存独立降低相关,且不依赖于AML进展。
研究设计与样本
- 回顾性分析486例诊断为MDS的输血患者,以时间依赖协变量评估红细胞免疫化的预后影响,并用竞争风险方法估计免疫化累积发生率。
主要发现
- MDS诊断前输血者免疫化风险更高(SHR 2.9,95%CI 1.6-5.4,p=0.001)。
- Rh(D)阴性血型者免疫化风险更高(SHR 1.9,95%CI 1.1-3.2,p=0.026)。
- 红细胞免疫化与剩余生存显著独立降低相关(HR 11.9,95%CI 7.3-19.6,p=0.001),自身抗体与同种抗体间无差异。
- 红细胞免疫化不预测向AML进展;免疫化后输血强度增加,但未免疫化患者输血需求也随时间上升。
临床怎么用
- 对输血依赖MDS患者应关注红细胞免疫化,其出现提示生存预后不良。
- MDS诊断前已输血或Rh(D)阴性血型患者需警惕免疫化风险。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite red blood cell (RBC) immunization being a frequent complication of chronic transfusion in myelodysplastic syndromes (MDS), its prognostic significance remains unclear. We analysed 486 transfused patients diagnosed with MDS. Prognostic impact of RBC immunization (allo- or autoantibodies) was evaluated as a time-dependent covariate. Competing risk methods were applied to estimate the cumulative incidence of immunization. Sixty-nine patients (14.2%) developed RBC immunization, most commonly anti-K and anti-E, which was more frequent in patients transfused before MDS diagnosis (subhazard ratio [SHR]: 2.9, 95% confidence interval [CI]: 1.6-5.4; p = 0.001) and Rh(D)-negative blood group (SHR: 1.9, 95% CI: 1.1-3.2; p = 0.026). RBC immunization was associated with a significant and independent reduction in remaining survival (hazard ratio: 11.9, 95% CI: 7.3-19.6; p = 0.001), without differences between auto- and alloantibodies. RBC immunization was followed by increased transfusion intensity, but transfusion requirements also rose in non-immunized patients over time. RBC immunization did not predict progression to acute myeloid leukaemia (AML). A trend towards fewer new antibodies was observed during hypomethylating therapy. RBC immunization is independently associated with reduced survival in transfusion-dependent patients with MDS, irrespective of AML progression. These findings highlight the potential prognostic relevance of RBC antibodies and call for further investigation into the mechanisms linking immunization, transfusion burden and survival outcomes.
引用
- Pedraza A, Castaño S, Pereira A, et al. Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes. Br J Haematol. 2026. PMID: 41560464. doi:10.1111/bjh.70330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。